Unknown

Dataset Information

0

Pilot Study of a Next-Generation Sequencing-Based Targeted Anticancer Therapy in Refractory Solid Tumors at a Korean Institution.


ABSTRACT: We evaluated the preliminary efficacy and feasibility of a next-generation sequencing (NGS)-based targeted anticancer therapy in refractory solid tumors at a Korean institution. Thirty-six patients with advanced cancer underwent molecular profiling with NGS with the intent of clinical application of available matched targeted agents. Formalin-fixed paraffin-embedded (FFPE) tumors were sequenced using the Comprehensive Cancer Panel (CCP) or FoundationOne in the Clinical Laboratory Improvement Amendments-certified laboratory in the USA. Response evaluations were performed according to RECIST v1.1. Four specimens did not pass the DNA quality test and 32 specimens were successfully sequenced with CCP (n = 31) and FoundationOne (n = 1). Of the 32 sequenced patients, 10 (31.3%) were ?40 years. Twelve patients (37.5%) had received ?3 types of prior systemic therapies. Of 24 patients with actionable mutations, five were given genotype-matched drugs corresponding to actionable mutations: everolimus to PIK3CA mutation in parotid carcinosarcoma (partial response) and tracheal squamous cell carcinoma (stable disease; 21% reduction), sorafenib to PDGFRA mutation in auditory canal adenocarcinoma (partial response), sorafenib to BRAF mutation in microcytic adnexal carcinoma (progressive disease), and afatinib to ERBB2 mutation in esophageal adenocarcinoma (progressive disease). Nineteen of 24 patients with actionable mutations could not undergo targeted therapy based on genomic testing because of declining performance status (10/24, 41.7%), stable disease with previous treatment (5/24, 20.8%), and lack of access to targeted medication (4/24, 16.7%). NGS-based targeted therapy may be a good option in selected patients with refractory solid tumors. To pursue this strategy in Korea, lack of access to clinical-grade NGS assays and a limited number of genotype-matched targeted medications needs to be addressed and resolved.

SUBMITTER: Park HS 

PROVIDER: S-EPMC4841558 | biostudies-literature | 2016

REPOSITORIES: biostudies-literature

altmetric image

Publications

Pilot Study of a Next-Generation Sequencing-Based Targeted Anticancer Therapy in Refractory Solid Tumors at a Korean Institution.

Park Hyung Soon HS   Lim Sun Min SM   Kim Sora S   Kim Sangwoo S   Kim Hye Ryun HR   Kwack KyuBum K   Lee Min Goo MG   Kim Joo-Hang JH   Moon Yong Wha YW  

PloS one 20160422 4


We evaluated the preliminary efficacy and feasibility of a next-generation sequencing (NGS)-based targeted anticancer therapy in refractory solid tumors at a Korean institution. Thirty-six patients with advanced cancer underwent molecular profiling with NGS with the intent of clinical application of available matched targeted agents. Formalin-fixed paraffin-embedded (FFPE) tumors were sequenced using the Comprehensive Cancer Panel (CCP) or FoundationOne in the Clinical Laboratory Improvement Ame  ...[more]

Similar Datasets

| S-EPMC6240710 | biostudies-literature
| S-EPMC9082754 | biostudies-literature
| S-EPMC8639101 | biostudies-literature
| S-EPMC5540534 | biostudies-literature
| S-EPMC4061055 | biostudies-literature
| S-EPMC5522060 | biostudies-other
| S-EPMC9315443 | biostudies-literature
| S-EPMC7873485 | biostudies-literature
| S-EPMC5293722 | biostudies-literature
| S-EPMC7034640 | biostudies-literature